An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1175, doi. 10.1007/s40273-023-01302-6
- By:
- Publication type:
- Article
Works matching IS 11707690 AND DT 2023 AND VI 41 AND IP 10
Results: 10
1
2
Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1165, doi. 10.1007/s40273-023-01300-8
- By:
- Publication type:
- Article
3
Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1229, doi. 10.1007/s40273-023-01292-5
- By:
- Publication type:
- Article
4
Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: An Updated Methodological Review.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1205, doi. 10.1007/s40273-023-01289-0
- By:
- Publication type:
- Article
5
Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1263, doi. 10.1007/s40273-023-01288-1
- By:
- Publication type:
- Article
6
Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: A Systematic Review.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1183, doi. 10.1007/s40273-023-01287-2
- By:
- Publication type:
- Article
7
Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1275, doi. 10.1007/s40273-023-01290-7
- By:
- Publication type:
- Article
8
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1287, doi. 10.1007/s40273-023-01285-4
- By:
- Publication type:
- Article
9
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1249, doi. 10.1007/s40273-023-01286-3
- By:
- Publication type:
- Article
10
Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1389, doi. 10.1007/s40273-023-01284-5
- By:
- Publication type:
- Article